Diverse FAP-targeting strategies have since been developed and tested in pre-clinical models, including genetic deletion [123,129], molecular inhibitors that block FAP enzymatic activity [129,183,184,185,186], anti-FAP monoclonal antibodies [187] and FAP-antigen vaccination [188], all with promising tumour-restraining results. Here, FAP is linked to neoplasm.